Asensus Surgical, Inc. to Release Fourth Quarter and Full Year 2022 Financial and Operating Results on March 2, 2023
February 27 2023 - 6:55AM
Asensus Surgical, Inc. (NYSE American: ASXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to pioneer a new era of Performance-Guided Surgery™,
announced today that it plans to release fourth quarter and full
year 2022 financial and operating results after the market closes
on Thursday, March 2, 2023.
As the Company hosted an Investor Day on Tuesday, February 21,
2023 during which an in-depth review of the business was provided,
the Company will not be hosting an earnings conference call in
conjunction with its earnings release.
A video replay of the Investor Day presentation is available
online on the investor relations page of the Company’s website at
https://ir.asensus.com/events-and-presentations.
About Asensus Surgical, Inc.
Asensus Surgical, Inc. is digitizing the interface between the
surgeon and patient to pioneer a new era of Performance-Guided
Surgery by unlocking clinical intelligence for surgeons to enable
consistently superior outcomes and a new standard of surgery. Based
upon the foundation of Digital Laparoscopy with the Senhance
Surgical System, the Company is developing the LUNA™ Surgical
System, a next generation robotic and instrument system as a
foundation of its Digital Surgery solution. These systems will be
powered by the Intelligent Surgical Unit™ to increase surgeon
control and reduce surgical variability. With the addition of
machine vision, Augmented Intelligence, and deep learning
capabilities throughout the surgical experience, we intend to
holistically address the current clinical, cognitive and economic
shortcomings that drive surgical outcomes and value-based
healthcare. The Senhance Surgical System is now available for sale
in the US, EU, Japan, Russia, and select other countries. For a
complete list of indications for use, visit:
www.senhance.com/indications. To learn more about
Performance-Guided Surgery, Digital Laparoscopy with the Senhance®
Surgical System and the new LUNA System visit www.asensus.com.
Follow Asensus
Email Alerts: https://ir.asensus.com/email-alerts
LinkedIn:
https://www.linkedin.com/company/asensus-surgical-inc
Twitter: https://twitter.com/AsensusSurgical
YouTube: https://www.youtube.com/c/transenterix
Vimeo: https://vimeo.com/asxc
Forward-Looking Statements
This press release includes statements relating to Asensus
Surgical. These statements and other statements regarding our
future plans and goals constitute "forward looking statements''
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934, and are
intended to qualify for the safe harbor from liability established
by the Private Securities Litigation Reform Act of 1995. Such
statements are subject to risks and uncertainties that are often
difficult to predict, are beyond our control and which may cause
results to differ materially from expectations. For a discussion of
the risks and uncertainties associated with the Company’s business,
please review our filings with the Securities and Exchange
Commission (SEC), including our Annual Report on Form 10-K for the
year ended December 31, 2021, filed with the SEC on February 28,
2022 and our other filings we make with the SEC. You are cautioned
not to place undue reliance on these forward looking statements,
which are based on our expectations as of the date of this press
release and speak only as of the origination date of this press
release. We undertake no obligation to publicly update or revise
any forward-looking statement, whether as a result of new
information, future events or otherwise.
INVESTOR CONTACT:
Mark Klausner or Mike Vallie, 443-213-0499
invest@asensus.com
MEDIA CONTACT:
Isabella Rodriguez, 708-833-1572
CG Life
irodriguez@cglife.com
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Asensus Surgical (AMEX:ASXC)
Historical Stock Chart
From Apr 2023 to Apr 2024